Fig. 6
From: Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
The anti-cath-D F1 antibody inhibits tumor growth of TNBC PDXs. a Cath-D expression in TNBC PDXs. Total cath-D expression was determined in whole cytosols from five TNBC PDXs by sandwich ELISA with immobilized anti-human cath-D D7E3 antibody and anti-human cath-D M1G8 antibody coupled to HRP. Total cath-D expression was quantified also in MDA-MB-231 tumor xenografts. b Cath-D expression in TNBC biopsies. Total cath-D expression was assessed in whole cytosols from TNBC biopsies as described in (a); n = 41. c Expression of cath-D in the PDX B1995 and B3977. Cath-D expression in the PDX B1995 (left panel) and PDX B3977 (right panel) primary tumors was monitored by IHC using a monoclonal anti-human cath-D (C-5; sc-377,127) antibody. Scale bar: 25 μm. Insets, high magnification of the boxed regions. d Average passage duration for the first three passages in the five TNBC PDXs. e Therapeutic effects of F1 in mice engrafted with PDX B1995 or PDX 3977. Mice were engrafted with PDX B1995 (left panel) or PDX B3977 (right panel) and when tumor volumes reached 150 mm3, mice were treated with F1 (15 mg/kg) or NaCl (CTRL) three times per week. Mice were sacrificed when tumor volume reached 2000 mm3 and the corresponding tumor growth curves were stopped. Tumor volume (in mm3) is shown as the mean ± SEM; For PDX B1995 : n = 7 for CTRL; n = 7 for F1. ***, P < 0.001 for F1. For PDX B3977 : n = 10 for CTRL; n = 10 for F1. *, P = 0.022 for F1